The short version of PPARδ agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-31 and is reviewed periodically as new material appears.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
An alternative model comes from studies that trace the evolution of proteins' structures in metabolic networks, this has suggested that enzymes are pervasively recruited, borrowing enzymes to perform similar functions in different metabolic pathways (evident in the MANET database) These recruitment processes result in an evolutionary enzymatic mosaic. A third possibility is that some parts of metabolism might exist as "modules" that can be reused in different pathways and perform similar functions on different molecules. As well as the evolution of new metabolic pathways, evolution can also cause the loss of metabolic functions. For example, in some parasites metabolic processes that are not essential for survival are lost and preformed amino acids, nucleotides and carbohydrates may instead be scavenged from the host. Similar reduced metabolic capabilities are seen in endosymbiotic organisms.
Level 1: COMP (exons 10–15) and MATN3 (exon 2) Level 2: COMP (exons 8 & 9 and 16–19) Level 3: COL9A1 (exon 8), COL9A2 and COL9A3 (exon 3) All those genes are involved in the production of the extracellular matrix (ECM). The role of COMP gene remains unclear. It is a noncollagenous protein of the ECM. Mutations in this gene can cause the pseudoachondroplasia (PSACH). It should play a role in the structural integrity of cartilage by its interaction with other extracellular matrix proteins and can be part of the interaction of the chondrocytes with the matrix and it is also a potent suppressor of apoptosis in chondrocytes. Another role is maintaining a vascular smooth muscle cells contractile under physiological or pathological stimuli. Since 2003, the European Skeletal Dysplasia Network has used an online system to diagnose cases referred to the network before mutation analysis to study the mutations causing PSACH or MED. COL9A1, COL9A2, COL9A3 are genes coding for collagen type IX, that is a component of hyaline cartilage. MATN3 protein may play a role in the formation of the extracellular filamentous networks and in the development and homeostasis of cartilage and bone. In the recessive form, the DTDST gene, also known as SLC26A2, is mutated in almost 90% of the patients, causing diastrophic dysplasia. It is a sulfate transporter, transmembrane glycoprotein implicated in several chondrodysplasias. It is important for sulfation of proteoglycans and matrix organization.
The relationships at the base of the animal tree have been debated. Other than Ctenophora, the Bilateria and Cnidaria are the only groups with symmetry, and other evidence shows they are closely related. In addition to sponges, Placozoa has no symmetry and was often considered a "missing link" between protists and multicellular animals. The presence of hox genes in Placozoa shows that they were once more complex. The Porifera (sponges) have long been assumed to be sister to the rest of the animals, but there is evidence that the Ctenophora may be in that position. Molecular phylogenetics has supported both the sponge-sister and ctenophore-sister hypotheses. In 2017, Roberto Feuda and colleagues, using amino acid differences, presented both, with the following cladogram for the sponge-sister view that they supported (their ctenophore-sister tree simply interchanging the places of ctenophores and sponges):
Curium ion in solution almost always has a +3 oxidation state, the most stable oxidation state for curium. A +4 oxidation state is seen mainly in a few solid phases, such as CmO2 and CmF4. Aqueous curium(IV) is only known in the presence of strong oxidizers such as potassium persulfate, and is easily reduced to curium(III) by radiolysis and even by water itself. The chemical behavior of curium is different from the actinides thorium and uranium, and is similar to americium and many lanthanides. In aqueous solution, the Cm3+ ion is colorless to pale green; Cm4+ ion is pale yellow. The optical absorption of Cm3+ ion contains three sharp peaks at 375.4, 381.2 and 396.5 nm and their strength can be directly converted into the concentration of the ions. The +6 oxidation state has only been reported once in solution in 1978, as the curyl ion (CmO2+2): this was prepared from beta decay of americium-242 in the americium(V) ion 242AmO+2. Failure to get Cm(VI) from oxidation of Cm(III) and Cm(IV) may be due to the high Cm4+/Cm3+ ionization potential and the instability of Cm(V). Curium ions are hard Lewis acids and thus form most stable complexes with hard bases. The bonding is mostly ionic, with a small covalent component. Curium in its complexes commonly exhibits a 9-fold coordination environment, with a tricapped trigonal prismatic molecular geometry.
Sources: en.wikipedia.org
Evidence from the study of extant Japanese macaques, indicating that the initial shift from quadrupedalism to bipedalism in the hominin evolution might have involved a shift of the primary action of the gluteus medius without any required morphological change, is presented by Shitara et al. (2026). Sekhavati, Prang & Strait (2026) study the relationships between hominin foot morphology and environmental context throughout the evolutionary history of hominins, and link the emergence of hominin bipedalism to increases of aridity in Central and Eastern Africa. Carlson et al. (2026) determine relative limb strength in Australopithecus and early members of the genus Homo, interpreted as indicative of frequent arboreal behavior in Australopithecus, as well as indicative of departure of hominins from arboreality by ∼1.8 million years ago. Kurki & Wall-Scheffler (2026) study the variation of pelvic canal dimensions in extant humans and extinct hominins, finding no evidence of a single trajectory of evolution of hominin pelvic shape. Komza, Viola & Schroeder (2026) interpret the evolution of the morphology of hominin midfoot as affected by selection for bipedalism in the lateral side in early bipeds such as Ardipithecus ramidus and shaped by a broad range of evolutionary processes in later hominins.
This same proposal was proposed again in 1976, but further studies indicated that the recurrence rate was not better. In 1888, treatments were tried that entered the abdomen to make reattachments. Some did not agree with this and suggested an approach through the inguinal canal. In 1898, further abdominal approaches were proposed. No further advances have been noted until 1961 when reattachment of the anterior vaginal wall to Cooper's ligament began to be used. Unfortunately, posterior vaginal wall prolapse occurred in some patients even though the anterior repair was successful. In 1955, using mesh to support pelvic structures became common. In 1970, tissue from pigs began to be used to strengthen the anterior vaginal wall in surgery. Beginning in 1976, improvement in suturing began along with the surgical removal of the vagina being used to treat prolapse of the bladder. In 1991, assumptions about the detailed anatomy of the pelvic support structures began to be questioned regarding the existence of some pelvic structures and the non-existence of others. More recently, stem cells and robot-assisted laparoscopic surgery have been used to treat cystoceles.
It is crucial to understand this when creating programs for the youth to avoid injury and/or overtraining. Since adolescents are still growing and are not done with developing not only musculature but also bone and joint structures. Younger children are at greater risk of injury than adults if they drop a weight on themselves or perform an exercise incorrectly. Furthermore, they may lack understanding of, or ignore the safety precautions around weight training equipment. As a result, supervision of minors is considered vital to ensuring the safety of any youth engaging in strength training.
== Transplanted human organoids == Bio- and electrical engineers have shown that human cerebral organoids transplanted into mice functionally integrate with their visual cortex. Such models may raise similar ethical issues as organoid-based humanization of other animals.
=== Glutathione's impact on cellular balance, diseases, and drug development === Townsend's research has focused on the multifaceted role of glutathione and glutathione S-transferase (GST) in human disease, particularly their involvement in anti-cancer drug resistance, protein S-glutathionylation, and redox stress. She explored GSH's role in maintaining cellular balance, serving as a co-factor for enzymes, and influencing posttranslational modifications. This work emphasized GSH's crucial role in combating reactive oxygen species (ROS), implicated in diseases such as cancer, neurodegenerative diseases, cystic fibrosis (CF), HIV, and aging. Collaborating with Tew, she investigated the role of GSTs in the development of resistance to chemotherapy agents, proposing them as inhibitors of the MAP kinase pathway and potential therapeutic targets for various diseases, including neurodegenerative diseases, multiple sclerosis, and asthma. Her studies identified a role for GSTs as enzymatic mediators of S-glutathionylation of proteins. In her further research on cancer chemotherapy, she explored how cisplatin selectively kills proximal tubule cells, identified its metabolic pathway to a nephrotoxin, and showed that the metabolism in these cells is crucial for cisplatin-induced kidney damage, suggesting new targets for inhibition.
Sources: en.wikipedia.org
=== Compounded versions === In the US, compounding pharmacies may prepare compounded versions of a drug on the Food and Drug Administration's (FDA) drug shortages list if the compounded drug meets certain conditions detailed in federal law. The FDA declared a shortage for Ozempic and Wegovy (but not Rybelsus) starting in August 2022. As of January 2026, there were up to 1.5 million users of compounded GLP-1 drugs (including semaglutide) in the United States, according to Novo Nordisk CEO Mike Doustdar. Some compounded versions contain salts of semaglutide, including the sodium and the acetate. The FDA cautioned that formulations containing semaglutide sodium or semaglutide acetate had not yet been shown to be safe and effective, and stated that moreover, the FDA does not evaluate compounded drugs for safety and effectiveness. The National Association of Boards of Pharmacy, a trade organization for pharmacy regulators, claims that there are tens of thousands of online pharmacies operating illegally or outside of the association's recommendations. Novo Nordisk has taken legal action against several businesses that it alleges are selling unfit semaglutide products.
ECD with UV-based activation increases the top-down MS sequence coverage of disulfide bond containing proteins and cleaves a disulfide bond homolytically to produce two separated thiol radicals. This technique was observed with insulin and ribonuclease, which led them to cleave up to three disulfide bonds and increase the sequence coverage.
== Academic career == Following his Ph.D. degree research into the pharmacokinetics of amphetamines, he took up a postdoctoral research appointment in the laboratory of Sidney Riegelman, School of Pharmacy, University of California, San Francisco (1965-1967), studying the pharmacokinetics of aspirin, and then took up a faculty position there (1967–75). While at UCSF. Rowland became a member of the joint Pharmacy-Medicine NIGMS funded program in Clinical Pharmacology, and moved his research from a prevailing descriptive approach to a more mechanistic, physiologically-based one, including the clearance concept that helped lay the foundations of modern pharmacokinetics. Together with Riegelman and Leslie Benet he founded the Journal of Pharmacokinetics and Biopharmaceutics (1973) (renamed Journal of Pharmacokinetics and Pharmacodynamics, 2001), and was a senior editor of it until 2007. In 1975 Rowland returned to the United Kingdom to take up a position of Professor of Pharmacy, University of Manchester where he extended his research on physiologically based pharmacokinetics including development of an in silico method for predicting tissue distribution of drugs based on tissue composition and physicochemical properties. In 1983 he founded Medeval, undertaking early stage clinical evaluation of new medicines under development. Together with Brian Houston and Leon Aarons he established the Centre for Applied Pharmacokinetic Research (1996). He has promoted the application of microdosing in clinical drug development.
18 October – A study indicates there has been a substantial increase of sentiment negativity and decrease of emotional neutrality in headlines across written popular news media since 2000. 19 October – A novel type of effective hydrogen storage using readily available salts is reported. 20 October A study of PNMN, the world's largest no-fishing zone, finds a "spillover benefit" for migratory species like bigeye and yellowfin tuna. The first data transmission to exceed 1 petabit per second (Pbit/s) using only a single laser and a single optical chip is demonstrated by European researchers. 21 October – News outlets report about a novel agricultural robot for viable weed control using lasers or "laserweeding". There are similar precision agriculture machines that have been reported before, also e.g. applying low amounts of herbicides and fertilizers with precision while mapping plant locations, in some cases autonomously. Their benefits may include "healthier crops and soil, decreased herbicide use, and reduced chemical and labor costs". 24 October The NHS launches 'Our Future Health', one of the world's largest health and genetic data gathering projects, aimed at building a long-term repository of information for researchers. Five million UK adults are invited to participate. "Hybrid viral particles (HVPs)" are reported, combining IAV and RSV in vitro. 25 October – A comprehensive annually scheduled study finds climate change is "undermining every dimension of global health monitored" and reports dire conclusions from tracking of impact indicators.
k¢ is the capacity factor of the complexed solute and the free solute k¢S is the capacity factor of the free solute KSM is the partition coefficient of the solute between the stationary phase and the micelle [M] may be either the concentration of surfactant or the concentration of micelle Foley used the above equation to determine the solute-micelle association constants and free solute retention factors for a variety of solutes with different surfactants and stationary phases. From this data, it is possible to predict the type and optimum surfactant concentrations needed for a given solute or solutes. Foley has not been the only researcher interested in determining the solute-micelle association constants. A review article by Marina and Garcia with 53 references discusses the usefulness of obtaining solute-micelle association constants. The association constants for two solutes can be used to help understand the retention mechanism. The separation factor of two solutes, a, can be expressed as KSM1/KSM2. If the experimental a coincides with the ratio of the two solute-micelle partition coefficients, it can be assumed that their retention occurs through a direct transfer from the micellar phase to the stationary phase. In addition, calculation of a would allow for prediction of separation selectivity before the analysis is performed, provided the two coefficients are known. The desire to predict retention behavior and selectivity has led to the development of several mathematical models.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.